QIAGEN Cash Flow from Operating Activities 2010-2025 | QGEN

QIAGEN cash flow from operating activities for the twelve months ending March 31, 2025 was $1.595B, a 47.14% increase year-over-year.

  • QIAGEN annual cash flow from operating activities for 2024 was $0.674B, a 46.6% increase from 2023.
  • QIAGEN annual cash flow from operating activities for 2023 was $0.459B, a 35.76% decline from 2022.
  • QIAGEN annual cash flow from operating activities for 2022 was $0.715B, a 11.93% increase from 2021.

QIAGEN Cash Flow from Operating Activities 2010-2025 | QGEN

  • QIAGEN annual cash flow from operating activities for 2024 was $0.674B, a 46.6% increase from 2023.
  • QIAGEN annual cash flow from operating activities for 2023 was $0.459B, a 35.76% decline from 2022.
  • QIAGEN annual cash flow from operating activities for 2022 was $0.715B, a 11.93% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.1B
Amgen (AMGN)$157.3B
Gilead Sciences (GILD)$135.7B
Vertex Pharmaceuticals (VRTX)$119.2B
Bristol Myers Squibb (BMY)$94.5B
CSL (CSLLY)$78.8B
GSK (GSK)$77.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$40.6B
Argenex SE (ARGX)$34B
BioNTech SE (BNTX)$26.6B
Royalty Pharma (RPRX)$20.5B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.2B
Moderna (MRNA)$12.2B
Exelixis (EXEL)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.4B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.3B
Revolution Medicines (RVMD)$7B